Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Once again, Dupixent finished in second place with an impressions SOV of 5.40% and 2.8 billion impressions. Notably, the ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

“After working with my dermatologist, she recommended I start Dupixent, a treatment for people ages 6 months and older with uncontrolled moderate-to-severe eczema.” Dupixent, known clinically ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Another, EVO301, could reach Phase 2 testing in a common type of eczema in 2025 as well ... Many of the experimental drugs in testing, among them Celldex’s barzovolimab and Sanofi and Regeneron’s ...

How Do You Calm an Eczema Flare-Up? If you suffer from eczema, it’s best to work with your dermatologist to find a treatment regimen that works for you. Get a cream or ask about a prescription ...